Hepatitis B virus (HBV) affects approximately 250 million patients worldwide, resulting in the progression to cirrhosis and hepatocellular carcinoma, which are serious public health problems. Although universal vaccination programs exist, they are only prophylactic and not curative. In the HBV life cycle, HBV forms covalently closed circular DNA (cccDNA), which is the viral minichromosome, in the nuclei of human hepatocytes and makes it difficult to achieve a complete cure with the current nucleos(t)ide analogs and interferon therapies. Current antiviral therapies rarely eliminate cccDNA; therefore, lifelong antiviral treatment is necessary. Recent trials for antiviral treatment of chronic hepatitis B have been focused on establishing a functional cure, defined by either the loss of hepatitis B surface antigen, undetectable serum HBV DNA levels, and/or seroconversion to hepatitis B surface antibody. Novel therapeutic targets and molecules are in the pipeline for early clinical trials aiming to cure HBV infection. The ideal strategy for achieving a long-lasting functional or complete cure might be using combination therapies targeting different steps of the HBV life cycle and immunomodulators. This review summarizes the current knowledge about novel treatments and combination treatments for a complete HBV cure.
Citations
Citations to this article as recorded by
Predictive factors for clinical cure in the treatment of HBeAg(−) chronic hepatitis B or compensated cirrhosis: a prospective observational study Yan-Qing Lv, Ru-Hua Guo, Kun-Yu Liu, Jia-Jie Li, Hui-Fan Ji Frontiers in Medicine.2025;[Epub] CrossRef
Cobalt Chloride–Mimicked Hepatocyte Cell Hypoxia Induces TREX1, Leading to Hepatitis B Virus Restriction Rodolphe Suspène, Vincent Caval, Pierre Khalfi, Emmanuelle Pitré, Agnès Marchio, Pascal Pineau, Jean-Pierre Vartanian The Journal of Infectious Diseases.2025; 231(6): 1559. CrossRef
The sV184A Variant in HBsAg Specific to HBV Subgenotype C2 Leads to Enhanced Viral Replication and Apoptotic Cell Death Induced by PERK‐eIF2α‐CHOP‐Mediated ER Stress Yu‐Min Choi, Dong Hyun Kim, Eun Ju Cho, Ziyun Kim, Junghwa Jang, Hyunsoo Kim, Su Jong Yu, Bum‐Joon Kim Journal of Medical Virology.2025;[Epub] CrossRef
Prediction of long-term HBsAg seroclearance in patients with HBeAg-negative chronic hepatitis B Hae Lim Lee, Soon Kyu Lee, Ji Won Han, Hyun Yang, Heechul Nam, Pil Soo Sung, Hee Yeon Kim, Sung Won Lee, Do Seon Song, Jung Hyun Kwon, Chang Wook Kim, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon, Jeong Won Jang JHEP Reports.2025; 7(7): 101391. CrossRef
Hepatocellular carcinoma in Korea: an analysis of the 2016-2018 Korean Nationwide Cancer Registry Jihyun An, Young Chang, Gwang Hyeon Choi, Won Sohn, Jeong Eun Song, Hyunjae Shin, Jae Hyun Yoon, Jun Sik Yoon, Hye Young Jang, Eun Ju Cho, Ji Won Han, Suk Kyun Hong, Ju-Yeon Cho, Kyu-Won Jung, Eun Hye Park, Eunyang Kim, Bo Hyun Kim Journal of Liver Cancer.2025; 25(1): 109. CrossRef
Functional Cure for Hepatitis B Virus: Challenges and Achievements Oren Shechter, Daniel G. Sausen, Harel Dahari, Andrew Vaillant, Scott J. Cotler, Ronen Borenstein International Journal of Molecular Sciences.2025; 26(8): 3633. CrossRef
Impact of hepatitis B surface antigen quantification on achieving a functional cure in patients with chronic hepatitis B: A systematic review and meta-analysis Shun Li, Lichen Shi, Cheng Huang, Min Li, Tongtong Meng, Hao Wang, Xinyu Zhao, Xiaoqian Xu, Hong You, Jidong Jia, Yuanyuan Kong Annals of Hepatology.2025; 30(2): 101921. CrossRef
A review of the progress and challenges of developing dendritic-based vaccines against hepatitis B virus (HBV) Ali Ameri, Hossein Gandomkar, Hanan Hassan Ahmed, Radhwan Abdul Kareem, Hayder Naji Sameer, Ahmed Yaseen, Zainab H. Athab, Mohaned Adil, Iman Ghasemzadeh Pathology - Research and Practice.2025; 271: 156025. CrossRef
mRNA-LNP vaccines against hepatitis B virus induce protective immune responses in preventive and chronic mouse challenge models María José Limeres, Rocio Gambaro, Malin Svensson, Silvia Fraude-El Ghazi, Leah Pretsch, Daniel Frank, German A. Islan, Ignacio Rivero Berti, Matthias Bros, Ying K. Tam, Hiromi Muramatsu, Norbert Pardi, Stephan Gehring, Maximiliano L. Cacicedo Molecular Therapy.2025; 33(9): 4156. CrossRef
Novel Therapeutics for Hepatocellular Carcinoma Mohamed I. Elsaid, Ashish Manne Clinics in Liver Disease.2025; 29(4): 673. CrossRef
Pathogenesis, prevention, and therapeutic advances in hepatitis B, C, and D Junjie Liu, Tong Yuan, Lin Xue, Huifang Liang Virology Journal.2025;[Epub] CrossRef
Advances in the computational development of hepatitis B virus capsid assembly modulators Ke Liu, Shaoqing Du, Weiqiao Deng, Zongjin Qu, Xueping Hu Drug Discovery Today.2025; 30(10): 104458. CrossRef
Emerging Trends and Future Directions in the Development of Anti-hepatitis B Therapies: A Horizon Scanning Review Kaijie Yao, Hao Feng, Ying Chen, Yun Bao, Mengxia Yan, Wen Li, Bin Wu Clinical Drug Investigation.2025; 45(10): 681. CrossRef
Magnitude of Hepatitis B virus and associated factors among chronic liver disease patients admitted to the medical ward at Sheikh Hassen Yabare Comprehensive Specialized Hospital, Jigjiga, Ethiopia: a retrospective study Ramadan Budul Yusuf, Getnet Addisu, Ahmed Mohammed Ibrahim, Terefe Gebre, Seid Muhumed Abdilaahi, Bilan Ali Ahmed, Abdulahi Hussen Abdinur, Girma Tadesse Wedajo, Mohamed Omar Osman, Tebelay Dilnessa PLOS One.2025; 20(12): e0338702. CrossRef
Overview of the immunological mechanisms in hepatitis B virus reactivation: Implications for disease progression and management strategies Hui Ma, Qing-Zhu Yan, Jing-Ru Ma, Dong-Fu Li, Jun-Ling Yang World Journal of Gastroenterology.2024; 30(10): 1295. CrossRef
Hepatitis B virus genotypes in precision medicine of hepatitis B-related hepatocellular carcinoma: Where we are now Caecilia H C Sukowati, Sri Jayanti, Turyadi Turyadi, David H Muljono, Claudio Tiribelli World Journal of Gastrointestinal Oncology.2024; 16(4): 1097. CrossRef
N-Hydroxypiridinedione: A Privileged Heterocycle for Targeting the HBV RNase H Dimitrios Moianos, Maria Makri, Georgia-Myrto Prifti, Aristeidis Chiotellis, Alexandros Pappas, Molly E. Woodson, Razia Tajwar, John E. Tavis, Grigoris Zoidis Molecules.2024; 29(12): 2942. CrossRef
SOD1 inhibition enhances sorafenib efficacy in HBV‐related hepatocellular carcinoma by modulating PI3K/Akt/mTOR pathway and ROS‐mediated cell death Jooyoung Lee, Jiye Kim, Ryunjin Lee, Eunkyeong Lee, Hye‐In An, Yong‐Jae Kwon, Hana Jin, Chan‐Gi Pack, Inki Kim, Young‐In Yoon, Gil‐Chun Park, Eun‐Kyoung Jwa, Jae Hyun Kwon, Jung‐Man Namgoong, Gi‐Won Song, Shin Hwang, Eunyoung Tak, Sung‐Gyu Lee Journal of Cellular and Molecular Medicine.2024;[Epub] CrossRef
Rupestonic Acid Derivative YZH-106 Promotes Lysosomal Degradation of HBV L- and M-HBsAg via Direct Interaction with PreS2 Domain Lanlan Liu, Haoyu Wang, Lulu Liu, Fang Cheng, Haji Akber Aisa, Changfei Li, Songdong Meng Viruses.2024; 16(7): 1151. CrossRef
Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction Mehrangiz Dezhbord, Seong Ho Kim, Soree Park, Da Rae Lee, Nayeon Kim, Juhee Won, Ah Ram Lee, Dong-Sik Kim, Kyun-Hwan Kim Clinical and Molecular Hepatology.2024; 30(3): 539. CrossRef
Diagnostic Utility of Pre-Genomic Hepatitis B RNA in the Evaluation of HBV/HIV Coinfection Kenneth Sherman, Susan Rouster, Heidi Meeds, Marion Peters, Jason Blackard, Paul Horn, Timothy Archampong, Awewura Kwara, Mark Anderson, Michael Stec, Gavin Cloherty Pathogens and Immunity.2024; 9(2): 43. CrossRef
Functional cure of chronic hepatitis B-hope or hype? Gautam Ray World Journal of Hepatology.2024; 16(9): 1199. CrossRef
Differential T-cell profiles determined by Hepatitis B surface antigen decrease among people with Human Immunodeficiency Virus /Hepatitis B Virus coinfection on treatment Xiaodi Li, Ling Xu, Lianfeng Lu, Xiaosheng Liu, Yang Yang, Yuanni Wu, Ting Zhu, Xiaoxia Li, Yanling Li, Xiaojing Song, Yang Han, Wei Lyu, Wei Cao, Taisheng Li Journal of Translational Medicine.2024;[Epub] CrossRef
Class II transactivator restricts viral replication, extending its effect to HBV: Editorial on “Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction” Cho-Rong Lee, Sung-Gyoo Park Clinical and Molecular Hepatology.2024; 30(4): 724. CrossRef
Correspondence on editorial regarding “Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction” Mehrangiz Dezhbord, Kyun-Hwan Kim Clinical and Molecular Hepatology.2024; 30(4): 1028. CrossRef
A case report: cccDNA and pgRNA remain positive in liver tissue in a chronic hepatitis B patient with functional cure Wenxiong Xu, Qiumin Luo, Yeqiong Zhang, Chan Xie, Liang Peng Frontiers in Medicine.2024;[Epub] CrossRef
Antiviral Therapy for Chronic Hepatitis B Infection Improves Outcomes After Total Hip Arthroplasty: A Multicenter Retrospective Study Tao Cheng, Guoyong Li, Huiming Ning, Liang Hao The Journal of Arthroplasty.2023; 38(2): 300. CrossRef
The emerging age-pattern changes of patients with hepatocellular carcinoma in Korea Yuri Cho, Bo Hyun Kim, Joong-Won Park Clinical and Molecular Hepatology.2023; 29(1): 99. CrossRef
Correspondence on Editorial regarding “HBV pgRNA and HBcrAg reductions at week 4 predict favourable HBsAg response upon long-term nucleos(t)ide analogue in CHB” Lung-Yi Mak, Wai-Kay Seto, Man-Fung Yuen Clinical and Molecular Hepatology.2023; 29(1): 191. CrossRef
Moving toward hepatitis B virus functional cure - the impact of on-treatment kinetics of serum viral markers Lilian Yan Liang, Vincent Wai-Sun Wong, Grace Lai-Hung Wong, Terry Cheuk-Fung Yip Clinical and Molecular Hepatology.2023; 29(1): 113. CrossRef
Overview of the development of HBV small molecule inhibitors Huihui Yang, Weiwei Yao, Jinfei Yang European Journal of Medicinal Chemistry.2023; 249: 115128. CrossRef
The progress of molecules and strategies for the treatment of HBV infection Youlu Pan, Heye Xia, Yanwen He, Shenxin Zeng, Zhengrong Shen, Wenhai Huang Frontiers in Cellular and Infection Microbiology.2023;[Epub] CrossRef
Spermidine enhances the efficacy of adjuvant in HBV vaccination in mice Daisuke Ito, Hiroyasu Ito, Tatsuya Ando, Yasuhiro Sakai, Takayasu Ideta, Ken J. Ishii, Tetsuya Ishikawa, Masahito Shimizu Hepatology Communications.2023;[Epub] CrossRef
The role of different viral biomarkers on the management of chronic hepatitis B Lung-Yi Mak, Rex Wan-Hin Hui, James Fung, Wai Kay Seto, Man-Fung Yuen Clinical and Molecular Hepatology.2023; 29(2): 263. CrossRef
The latest global burden of liver cancer: A past and present threat Joo Hyun Oh, Dae Won Jun Clinical and Molecular Hepatology.2023; 29(2): 355. CrossRef
Interactions of Na+/taurocholate cotransporting polypeptide with host cellular proteins upon hepatitis B and D virus infection: novel potential targets for antiviral therapy Dariusz Zakrzewicz, Joachim Geyer Biological Chemistry.2023; 404(7): 673. CrossRef
Comparison of decline in renal function between patients with chronic hepatitis B with or without antiviral therapy Jae Seung Lee, Chan‐Young Jung, Jung Il Lee, Sang Hoon Ahn, Beom Seok Kim, Seung Up Kim Alimentary Pharmacology & Therapeutics.2023; 58(1): 99. CrossRef
Changes in liver stiffness values assessed using transient elastography in chronic hepatitis B patients treated with tenofovir disoproxil fumarate: a prospective observational study Heejin Cho, Yun Bin Lee, Yeonjung Ha, Young Eun Chon, Mi Na Kim, Joo Ho Lee, Hana Park, Kyu Sung Rim, Seong Gyu Hwang BMC Gastroenterology.2023;[Epub] CrossRef
Prediction model of hepatitis B virus-related hepatocellular carcinoma in patients receiving antiviral therapy Beom Kyung Kim, Sang Hoon Ahn Journal of the Formosan Medical Association.2023; 122(12): 1238. CrossRef
Development of Therapy Based on the Exploration of Biological Events Underlying the Pathogenetic Mechanisms of Chronic Hepatitis B Infection Sheikh Mohammad Fazle Akbar, Mamun Al Mahtab, Osamu Yoshida, Julio Aguilar, Guillen Nieto Gerardo, Yoichi Hiasa Biomedicines.2023; 11(7): 1944. CrossRef
Chronic Hepatitis B Infection: Current and Emerging Therapeutic
Strategies Ankita Singh, Jitendra Kumar, Vijay Kumar Current Topics in Medicinal Chemistry.2023; 23(18): 1727. CrossRef
Current Status and Challenges in Anti-Hepatitis B Virus Agents Based on Inactivation/Inhibition or Elimination of Hepatitis B Virus Covalently Closed Circular DNA An-Qi Zhuang, Yan Chen, Shan-Mei Chen, Wen-Cheng Liu, Yao Li, Wen-Jie Zhang, Yi-Hang Wu Viruses.2023; 15(12): 2315. CrossRef
Multitasking Na+/Taurocholate Cotransporting Polypeptide (NTCP) as a Drug Target for HBV Infection: From Protein Engineering to Drug Discovery Dariusz Zakrzewicz, Joachim Geyer Biomedicines.2022; 10(1): 196. CrossRef
Genotypes Variation and Molecular Epidemiology Of The Hbv Chronic Liver Infection In The Local Population Of Pakistan: An Overview Of The Recent Literature Bushra Tahreem, Ghadir Ali, Haroon Ahmad, Asim Shahzad, Muhammad Khurram, Nabiha Naeem, Aquib Nazar, Muhammad Haris, Hassan ., Shahrukh . Pakistan BioMedical Journal.2022;[Epub] CrossRef
KASL clinical practice guidelines for management of chronic hepatitis B
Clinical and Molecular Hepatology.2022; 28(2): 276. CrossRef
Current Status of Drug Therapy for Chronic Hepatitis B 显明 尹 Advances in Clinical Medicine.2022; 12(07): 6196. CrossRef
Similar risk of kidney function decline between tenofovir alafenamide and besifovir dipivoxil maleate in chronic hepatitis B Chan‐Young Jung, Hyung Woo Kim, Jung Il Lee, Hyun Woong Lee, Sang Hoon Ahn, Seung Up Kim, Beom Seok Kim Liver International.2022; 42(11): 2408. CrossRef
Design, Synthesis and Evaluation of Novel 4‐(4‐Chlorobenzyl)‐6‐methylpyridazin‐3(2H)‐one Derivatives as Hepatitis B Virus Inhibitors Oya Unsal Tan, Jan Moncol, David Durantel ChemistrySelect.2022;[Epub] CrossRef
Hepatitis B functional cure and immune response Jia-Rui Zheng, Zi-Long Wang, Bo Feng Frontiers in Immunology.2022;[Epub] CrossRef
Suboptimal Performance of Hepatocellular Carcinoma Prediction Models in Patients with Hepatitis B Virus-Related Cirrhosis Jae Lee, Tae Lim, Hye Lee, Seung Kim, Jun Park, Do Kim, Sang Ahn, Hyun Lee, Jung Lee, Ja Kim, In Min, Beom Kim Diagnostics.2022; 13(1): 3. CrossRef
Critical Updates on Chronic Hepatitis B Virus Infection in 2021 Cyriac A Philips, Rizwan Ahamed, Jinsha K Abduljaleel, Sasidharan Rajesh, Philip Augustine Cureus.2021;[Epub] CrossRef
Cheol-Hyung Lee, Yun Bin Lee, Minseok Albert Kim, Heejoon Jang, Hyunwoo Oh, Sun Woong Kim, Eun Ju Cho, Kyung-Hun Lee, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Tae-You Kim, Yoon Jun Kim
Clin Mol Hepatol 2020;26(3):328-339. Published online May 28, 2020
Background/Aims Several treatment options are currently available for patients with hepatocellular carcinoma (HCC) failing previous sorafenib treatment. We aimed to compare the effectiveness of regorafenib and nivolumab in these patients.
Methods Consecutive HCC patients who received regorafenib or nivolumab after failure of sorafenib treatment were included. Primary endpoint was overall survival (OS) and secondary endpoints were time to progression, tumor response rate, and adverse events. Inverse probability of treatment weighting (IPTW) using the propensity score was conducted to reduce treatment selection bias.
Results Among 150 study patients, 102 patients received regorafenib and 48 patients received nivolumab. Median OS was 6.9 (95% confidence interval [CI], 3.0–10.8) months for regorafenib and 5.9 (95% CI, 3.7–8.1) months for nivolumab (P=0.77 by log-rank test). In multivariable analysis, nivolumab was associated with prolonged OS (vs. regorafenib: adjusted hazard ratio [aHR], 0.54; 95% CI, 0.30–0.96; P=0.04). Time to progression was not significantly different between groups (nivolumab vs. regorafenib: aHR, 0.82; 95% CI, 0.51–1.30; P=0.48). HRs were maintained after IPTW. Objective response rates were 5.9% and 16.7% in patients treated with regorafenib and nivolumab, respectively (P=0.04).
Conclusions After sorafenib failure, the use of nivolumab may be associated with improved OS and better objective response rate as compared to using regorafenib.
Citations
Citations to this article as recorded by
Effectiveness of regorafenib in second-line therapy for advanced hepatocellular carcinoma: A systematic review and meta-analysis Yunzhi Shen, Yu Bai Medicine.2025; 104(4): e41356. CrossRef
Efficacy and Safety of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Muhammad A.B. Naeem, Muhammad R. Paracha, Ahmad Noor, Muhammad H.A. Khalid, Hafiza K. Shahid, Maaz Khan, Moeaza R. Rizvi, Javeeria Arshad, Talha Abbas, Azeem Saeed, Hamza Ashraf, Minahil Ali, Mishal Asif, Aanusha Ghouri American Journal of Clinical Oncology.2025;[Epub] CrossRef
Impact of post‐progression survival in second‐line treatment with molecular target agents for unresectable hepatocellular carcinoma Kazuto Tajiri, Nozomu Muraishi, Aiko Murayama, Yuka Hayashi, Ichiro Yasuda Hepatology Research.2024; 54(4): 403. CrossRef
Approved immune checkpoint inhibitors in hepatocellular carcinoma: a large-scale meta-analysis and systematic review Ruyi Zhang, Fang Wang, Zhiyu You, Dongyang Deng, Jiangyan He, Wentao Yan, Jian Quan, Jing Wang, Shujuan Yan Journal of Cancer Research and Clinical Oncology.2024;[Epub] CrossRef
Comparison between Nivolumab and Regorafenib as Second-line Systemic Therapies after Sorafenib Failure in Patients with Hepatocellular Carcinoma Hong Jun Lee, Jae Seung Lee, Hyesung So, Ja Kyung Yoon, Jin-Young Choi, Hye Won Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Sang Hoon Ahn, Do Young Kim Yonsei Medical Journal.2024; 65(7): 371. CrossRef
Nivolumab as Second-Line Therapy Improves Survival in Patients with Unresectable Hepatocellular Carcinoma Faisal M. Sanai, Hassan O. Odah, Kanan Alshammari, Adnan Alzanbagi, Murooj Alsubhi, Hani Tamim, Ashwaq Alolayan, Ahmed Alshehri, Saleh A. Alqahtani Cancers.2024; 16(12): 2196. CrossRef
The interdisciplinary approach to investigate bona fide agent(s) in flavonoids or alkaloids in treating HCC Ki-Kwang Oh, Sang-Jun Yoon, Seol Hee Song, Jeong Ha Park, Jeong Su Kim, Min Ju Kim, Goo-Hyun Kwon, Dong Joon Kim, Ki-Tae Suk Artificial Cells, Nanomedicine, and Biotechnology.2024; 52(1): 500. CrossRef
Efficacy and Safety of PD-1/PD-L1 Inhibitors in Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-analysis Yuwei Liu, Jiahui Pan, Fangbo Gao, Wentao Xu, Hongyu Li, Xingshun Qi Advances in Therapy.2023; 40(2): 521. CrossRef
Evaluating liver function and the impact of immune checkpoint inhibitors in the prognosis of hepatocellular carcinoma patients: A systemic review and meta-analysis Bao-Wen Tian, Lun-Jie Yan, Zi-Niu Ding, Hui Liu, Cheng-Long Han, Guang-Xiao Meng, Jun-Shuai Xue, Zhao-Ru Dong, Yu-Chuan Yan, Jian-Guo Hong, Zhi-Qiang Chen, Dong-Xu Wang, Tao Li International Immunopharmacology.2023; 114: 109519. CrossRef
Sorafenib versus nivolumab after lenvatinib treatment failure in patients with advanced hepatocellular carcinoma Yuna Kim, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Myung Ji Goh, Wonseok Kang, Seung Up Kim European Journal of Gastroenterology & Hepatology.2023; 35(2): 191. CrossRef
Immunotherapy and the Combination with Targeted Therapies for Advanced Hepatocellular Carcinoma Carmelo Laface, Girolamo Ranieri, Felicia Maria Maselli, Francesca Ambrogio, Caterina Foti, Michele Ammendola, Marigia Laterza, Gerardo Cazzato, Riccardo Memeo, Giovanni Mastrandrea, Marco Lioce, Palma Fedele Cancers.2023; 15(3): 654. CrossRef
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Prognostic factors of nivolumab in advanced hepatocellular carcinoma: a systematic review and meta-analysis Ding XIONG, Kui ZHANG, Mingqing XU Panminerva Medica.2023;[Epub] CrossRef
Systemic Therapy for Hepatocellular Carcinoma: Current Updates and Outlook Yinjie Fan, Hang Xue, Huachuan Zheng Journal of Hepatocellular Carcinoma.2022; Volume 9: 233. CrossRef
Intrahepatic inflammatory IgA+PD-L1high monocytes in hepatocellular carcinoma development and immunotherapy Pil Soo Sung, Dong Jun Park, Pu Reun Roh, Kyoung Do Mun, Sung Woo Cho, Gil Won Lee, Eun Sun Jung, Sung Hak Lee, Jeong Won Jang, Si Hyun Bae, Jong Young Choi, Jonghwan Choi, Jaegyoon Ahn, Seung Kew Yoon Journal for ImmunoTherapy of Cancer.2022; 10(5): e003618. CrossRef
Durable objective response to sorafenib and role of sequential treatment in unresectable hepatocellular carcinoma Kuo-Wei Huang, Pei-Chang Lee, Yee Chao, Chien-Wei Su, I-Cheng Lee, Keng-Hsin Lan, Chi-Jen Chu, Yi-Ping Hung, San-Chi Chen, Ming-Chih Hou, Yi-Hsiang Huang Therapeutic Advances in Medical Oncology.2022;[Epub] CrossRef
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Clinical and Molecular Hepatology.2022; 28(4): 583. CrossRef
2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma
Korean Journal of Radiology.2022; 23(12): 1126. CrossRef
Blood-based biomarkers for immune-based therapy in advanced HCC: Promising but a long way to go Pil Soo Sung, Isaac Kise Lee, Pu Reun Roh, Min Woo Kang, Jaegyoon Ahn, Seung Kew Yoon Frontiers in Oncology.2022;[Epub] CrossRef
Real-world systemic sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Korea Min Jin Lee, Sung Won Chang, Ji Hoon Kim, Young-Sun Lee, Sung Bum Cho, Yeon Seok Seo, Hyung Joon Yim, Sang Youn Hwang, Hyun Woong Lee, Young Chang, Jae Young Jang Investigational New Drugs.2021; 39(1): 260. CrossRef
Targeted treatment of alcoholic liver disease based on inflammatory signalling pathways Bingjian Wen, Chengcheng Zhang, Jingwen Zhou, Zhengyan Zhang, Qishi Che, Hua Cao, Yan Bai, Jiao Guo, Zhengquan Su Pharmacology & Therapeutics.2021; 222: 107752. CrossRef
Surgery versus external beam radiotherapy for hepatocellular carcinoma involving the inferior vena cava or right atrium: A systematic review and meta‐analysis Han Ah Lee, Sunmin Park, Yeon Seok Seo, Won Sup Yoon, In‐Soo Shin, Chai Hong Rim Journal of Hepato-Biliary-Pancreatic Sciences.2021; 28(12): 1031. CrossRef
The Efficacy and Safety of Programmed Death-1 and Programmed Death Ligand 1 Inhibitors for the Treatment of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis Shukang He, Weichao Jiang, Kai Fan, Xiaobei Wang Frontiers in Oncology.2021;[Epub] CrossRef
Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma Sojung Han, Hye Jin Choi, Seung-Hoon Beom, Hye Rim Kim, Hyein Lee, Jae Seung Lee, Hye Won Lee, Jun Yong Park, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Jinsil Seong, Jong Yun Won, Beom Kyung Kim Journal of Cancer Research and Clinical Oncology.2021; 147(10): 3123. CrossRef
Evolving therapeutic strategies for advanced hepatocellular carcinoma Ammar Qureshi, Miguel Michel, Jaren Lerner, Constantin A. Dasanu Expert Opinion on Pharmacotherapy.2021; 22(18): 2495. CrossRef
Metformin and Dichloroacetate Suppress Proliferation of Liver Cancer Cells by Inhibiting mTOR Complex 1 Tae Suk Kim, Minjong Lee, Minji Park, Sae Yun Kim, Min Suk Shim, Chea Yeon Lee, Dae Hee Choi, Yuri Cho International Journal of Molecular Sciences.2021; 22(18): 10027. CrossRef
Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure Yuan-Hung Kuo, Yi-Hao Yen, Yen-Yang Chen, Kwong-Ming Kee, Chao-Hung Hung, Sheng-Nan Lu, Tsung-Hui Hu, Chien-Hung Chen, Jing-Houng Wang Frontiers in Oncology.2021;[Epub] CrossRef
Knockdown of Atg7 suppresses Tumorigenesis in a murine model of liver cancer Kyung Joo Cho, Sun Yeong Shin, Hyuk Moon, Beom Kyung Kim, Simon Weonsang Ro Translational Oncology.2021; 14(9): 101158. CrossRef
Systemic therapy for advanced hepatocellular carcinoma: consideration for selecting second-line treatment Bo Hyun Kim, Joong-Won Park Journal of Liver Cancer.2021; 21(2): 124. CrossRef
Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review Kyoko Oura, Asahiro Morishita, Joji Tani, Tsutomu Masaki International Journal of Molecular Sciences.2021; 22(11): 5801. CrossRef
Potential predictors for survival in hepatocellular carcinoma patients treated with immune checkpoint inhibitors: A meta-analysis Huilin Xu, Dedong Cao, Yongfa Zheng, Dingjie Zhou, Xin Chen, Jinju Lei, Wei Ge, Ximing Xu International Immunopharmacology.2021; 100: 108135. CrossRef
Comparative Analysis of Lenvatinib and Hepatic Arterial Infusion Chemotherapy in Unresectable Hepatocellular Carcinoma: A Multi-Center, Propensity Score Study Jaejun Lee, Ji-Won Han, Pil-Soo Sung, Soon-Kyu Lee, Hyun Yang, Hee-Chul Nam, Sun-Hong Yoo, Hae-Lim Lee, Hee-Yeon Kim, Sung-Won Lee, Jung-Hyun Kwon, Jeong-Won Jang, Chang-Wook Kim, Soon-Woo Nam, Jung-Suk Oh, Ho-Jong Chun, Si-Hyun Bae, Jong-Young Choi, Seun Journal of Clinical Medicine.2021; 10(18): 4045. CrossRef
Optimal sequence of systemic therapy after sorafenib failure in patients with hepatocellular carcinoma Sojung Han, Do Young Kim Clinical and Molecular Hepatology.2020; 26(3): 305. CrossRef
Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma Mohamed A. Abd El Aziz, Antonio Facciorusso, Tarek Nayfeh, Samer Saadi, Mohamed Elnaggar, Christian Cotsoglou, Rodolfo Sacco Vaccines.2020; 8(4): 616. CrossRef
First
Prev
